HXL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hexcel Corp (HXL) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has shown strong financial growth in the last quarter and has positive analyst sentiment, the technical indicators suggest a bearish short-term trend. Additionally, the options data and lack of significant trading signals do not indicate strong momentum for immediate entry.
The MACD is negative and expanding downward, indicating bearish momentum. The RSI at 37.882 is neutral but leaning toward oversold territory. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 91.277, with key support at 87.988 and resistance at 94.566. Overall, the technical indicators suggest caution.
Hedge funds are significantly increasing their positions in the stock, with a 593.28% increase in buying over the last quarter.
Analysts have raised price targets, with several upgrades and a consensus target range of $85-$
Strong Q4 financial performance with a 700% YoY increase in net income and 757.14% YoY EPS growth.
MACD and RSI suggest short-term bearish momentum.
Gross margin dropped by 1.52% YoY, indicating potential cost pressures.
Stock trend analysis shows a 70% chance of declining by 3.62% in the next week and 7.24% in the next month.
No recent congress trading data or significant insider activity to support a strong buy case.
In Q4 2025, Hexcel reported a revenue increase of 3.69% YoY to $491.3 million. Net income surged by 700% YoY to $46.4 million, and EPS increased by 757.14% YoY to $0.6. However, gross margin dropped slightly to 24.63%, down 1.52% YoY.
Analysts have a mixed to positive sentiment on HXL. Recent upgrades include BofA upgrading to Neutral with a price target of $95 and RBC Capital raising its target to $95 with an Outperform rating. Morgan Stanley highlighted strong growth potential with a 27% annual earnings growth forecast through 2028. However, some analysts, like BMO Capital, remain cautious due to the stock's high valuation.
